Touro Scholar
NYMC Faculty Publications

Faculty

4-1-2018

Effects of Atypical Antipsychotic Drugs on QT Interval in Patients
with Mental Disorders
Wilbert S. Aronow
New York Medical College

Tatyana Shamliyan

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Aronow, W. S., & Shamliyan, T. (2018). Effects of Atypical Antipsychotic Drugs on QT Interval in Patients
with Mental Disorders. Annals of Translational Medicine, 6 (8), 147. https://doi.org/10.21037/
atm.2018.03.17

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information,
please contact touro.scholar@touro.edu.

Original Article

Page 1 of 26

Effects of atypical antipsychotic drugs on QT interval in patients
with mental disorders
Wilbert S. Aronow1, Tatyana A. Shamliyan2
1

Department of Cardiology, Westchester Medical Center, New York Medical College, Valhalla, NY, USA; 2Quality Assurance, Evidence-Based

Medicine Center, Elsevier, Philadelphia, PA, USA
Contributions: (I) Conception and design: All authors; (II) Administrative support: TA Shamliyan; (III) Provision of study materials or patients: TA
Shamliyan; (IV) Collection and assembly of data: TA Shamliyan; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All
authors; (VII) Final approval of manuscript: All authors.
Correspondence to: Tatyana A. Shamliyan, MD, MS. Quality Assurance, Evidence-Based Medicine Center, Elsevier, 1600 JFK Blvd, Philadelphia, PA
19103, USA. Email: t.shamliyan@elsevier.com.

Background: Drug-induced QT prolongation is associated with higher risk of cardiac arrhythmias and
cardiovascular mortality. We investigated the effects of atypical antipsychotic drugs on QT interval in
children and adults with mental disorders.
Methods: We conducted random-effects direct frequentist meta-analyses of aggregate data from
randomized controlled trials (RCT) and appraised the quality of evidence using the Grading of
Recommendations Assessment, Development and Evaluation (GRADE) methodology. Our search
in PubMed, EMBASE, the Cochrane Library, clinicaltrials.gov, and PharmaPendium up to October
2017 identified studies that examined aripiprazole, quetiapine, risperidone, olanzapine, ziprasidone and
brexpiprazole.
Results: Low quality evidence suggests that aripiprazole (four meta-analyses and twelve RCTs),
brexpiprazole (one systematic review and four RCTs) or olanzapine (five meta-analyses and twenty RCTs) do
not increase QT interval. Low quality evidence suggests that ziprasidone (five meta-analyses and 11 RCTs)
increases QT interval and the rates of QT prolongation while risperidone (four meta-analyses, 70 RCTs) and
quetiapine (two meta-analyses and seven RCTs) are associated with QT prolongation and greater odds of
torsades de pointes ventricular tachycardia especially in cases of drug overdose.
Conclusions: The main conclusion of our study is that in people with mental disorders and under
treatment with atypical antipsychotic drugs, in order to avoid QT prolongation and reduce the risk of
ventricular tachycardia clinicians may recommend aripiprazole, brexpiprazole or olanzapine in licensed
doses. Long-term comparative safety needs to be established.
Keywords: Quality of evidence; cardiovascular morbidity; drug-induced QT prolongation; aripiprazole;
quetiapine; risperidone; olanzapine; ziprasidone; brexpiprazole
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Introduction
Observational studies provide consistent evidence that
prolonged QT interval is associated with higher risk of
all-cause and cardiovascular mortality (1). Drug-induced
prolongation of QT contributes to higher mortality (2,3).
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The risk of drug-induced prolongation of QT is much
higher in older adults and people with multiple chronic
conditions (4). Psychotropic drugs including atypical
antipsychotic agents are commonly prescribed for licensed
and off-label indications and may contribute to the higher
risk of drug-induced QT prolongation (5,6). This rapid
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review focuses on the effects of atypical antipsychotic
drugs on QT interval in children and adults with mental
disorders.
Methods
We used a standard recommended methodology in
conducting systematic literature reviews and meta-analyses
from the Cochrane Collaboration and the Agency for
Healthcare Research and Quality (7,8). We developed
a priori protocol for a systematic literature review to
answer the clinical question about the safety of atypical
antipsychotic drugs on QT interval in children and adults
with mental disorders.
We defined the target population as people with mental
disorders treated with atypical antipsychotic drugs. Eligible
interventions included atypical antipsychotics when
compared with placebo or other antipsychotic medications.
Eligible outcomes included change in QT Interval,
clinically important prolongation of QT corrected to RR
interval ≥450 msec in men ≥480 msec in women, and QTc
≥500 msec associated with increased risk of life-threatening
torsades de pointes ventricular tachycardia (9).
We conducted a comprehensive search in PubMed,
EMBASE, the Cochrane Library, www.clinicaltrials.gov
and PharmaPendium (www.pharmapendium.com) up to
October 2017 to find systematic reviews, published and
unpublished RCTs, and nationally represented controlled
observational studies that reported adjusted effect estimates
(7,8). All of the authors determined the studies’ eligibility.
All citations found during the searches are stored in a
reference database.
The data was extracted from the Clinical Trials
Transformation Initiative (CTTI) (https://www.ctticlinicaltrials.org/aact-database), checked for quality,
and stored in the HPCC platform (High-Performance
Computing Cluster, https://hpccsystems.com/).
We performed direct frequentist meta-analyses of
aggregate data when definitions of the active and control
intervention and patient outcomes were deemed similar
for pooling (10). We used random effects models to
address inevitable differences in patient characteristics
across primary RCTs. For each abstracted hypothesis, we
calculated absolute risk difference and relative risk with
95% CI. We calculated number needed to treat and number
of attributable events per 1,000 treated with 95% CI based
on statistically significant differences in absolute risks of
the outcomes. We examined consistency in results across
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studies with chi-square tests and I2 statistics and concluded
statistically significant heterogeneity if I2 was >50% (7).
Statistically significant heterogeneity did not preclude
statistical pooling (10). However, we planned exploring
heterogeneity with a priori defined patient characteristics,
drug doses, and study quality if this information was
available in the studies (10).
We used consensus method guidelines for systematic
review and meta-analyses that do not recommend
conducting post hoc analyses of statistical power (11-14).
Instead, we downgraded our confidence in true treatment
effects based on calculated optimal information size as the
number of patients required for an adequately powered
individual trial (15). Since power is more closely related
to number of events than to sample size, we concluded
imprecision in treatment effects if fewer than 250 patients
experienced the event (15).
We used Statistics/Data Analysis, STATA software
(StataCorp LP, College Station, Texas). Statistical
significance was evaluated at a 95% confidence level.
We evaluated the quality of systematic reviews using the
Assessment of Multiple Systematic Reviews (AMSTAR) (16).
For primary RCTs, we used the Cochrane risk of bias tool
on a 3-point scale: high bias, low bias, and unclear (17,18).
A low risk of bias was assumed when RCTs met all the riskof-bias criteria, a medium risk of bias if at least 1 of the riskof-bias criteria was not met, and a high risk of bias if two or
more risk-of-bias criteria were not met. An unknown risk
of bias was assigned for the studies with poorly reported
risk-of-bias criteria. We assigned high risk of bias to all
observational studies.
The authors assigned the quality of evidence ratings as
high, moderate, low, or very low, according to risk of bias in
the body of evidence, directness of comparisons, precision
and consistency in treatment effects, and the evidence
of reporting bias, using Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
methodology (19).
A high quality of evidence was assigned to well-designed
RCTs with consistent findings. The quality of evidence
was downgraded to moderate if at least 1 of 4 quality of
evidence criteria was not met; for example, moderate quality
of evidence was assigned if there was a high risk of bias in
the body of evidence or if the results were not consistent
or precise. The quality of evidence was downgraded to low
if two or more criteria were not met. We concluded a high
risk of bias in the body of evidence if at least one RCT had
high risk of bias. We downgraded the quality of evidence
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when we suspected high risk of publication bias due to
unavailability of the results in clinicaltrials.gov or journal
articles.
A low quality of evidence was assigned to nonrandomized
studies, but the rating was upgraded if there was a
strong or dose-response association (20). Evidence was
defined as insufficient when no studies provided valid
information about treatment effects. This approach was
applied regardless of whether the results were statistically
significant.
Results
Our comprehensive search in PubMed, EMBASE, the
Cochrane Library, and clinicaltrials.gov up to May 2017
identified clinical studies that examined aripiprazole,
quetiapine, risperidone, olanzapine, ziprasidone or
brexpiprazole.
Risperidone was examined in three systematic reviews
and meta-analyses, one individual patient data network
meta-analysis of 64 RCTs, published and unpublished data
from six RCTs and six non-randomized studies (21-40).
Evidence suggests that risperidone is associated with
QT prolongation in children and adolescents with mental
disorders (Table 1).
A single industry-sponsored individual patient metaanalysis of 64 RCTs suggests that risperidone results in QT
prolongation when compared with placebo in adults with
mental disorders (Table 1). The evidence from the FDA
Adverse Event Reporting System database suggests that
risperidone is associated with greater odds of torsades de
pointes ventricular tachycardia in adults with indication
for antipsychotics (Table 1). Industry—sponsored postmarketing analysis suggests that all cases of ventricular
tachycardia have been associated with overdose of
risperidone (41).
The direct evidence of comparative safety between
risperidone and other antipsychotics is sparse. Risperidone
is associated with QT abnormalities when compared with
aripiprazole in pediatric patients with mental disorders and
concomitant use of stimulants (Table 2). Some evidence
suggests that there are no differences in QT abnormalities
or rates of torsades de pointes between risperidone and
atypical antipsychotics or haloperidol in adults with mental
disorders (Table 2). A single RCT suggests that risperidone
decreases QT interval when compared with ziprasidone
(Table 2).
Post-marketing surveillance suggests 43 cases of
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prolonged QT intervals and 71 cases of torsades de pointes
tachycardia in people treated with risperidone among other
medications for various mental disorders (Table S1).
Ziprasidone was examined in four systematic reviews
and meta-analyses, one industry sponsored individual
patient data network meta-analysis and published and
unpublished data from 11 RCTs and three non-randomized
trials (30,35,37,38,42-56).
Evidence suggests that ziprasidone increases QT
interval and the rates of QT prolongation by >30 msec
when compared with placebo (Table 3) or haloperidol
(Table 4) in people with mental disorders. Ziprasidone also
prolongs QT interval when compared with olanzapine
and risperidone (Table 5). There are no differences in the
length of QT interval after treatment with ziprasidone
versus aripiprazole (Table 5). Chlorpromazine increases the
duration of QT interval when compared with ziprasidone
(Table 5).
Available studies did not report the rates of torsade
de pointes ventricular tachycardia in adults treated with
ziprasidone. Post-marketing observational study suggested
no differences in mortality after 1-year treatments with
ziprasidone versus olanzapine in 18,154 adults with
schizophrenia (Table S2). Post-marketing surveillance
identified 202 cases of prolonged QT interval and 83 cases
of torsade de pointes in patients treated with ziprasidone
among other drugs (Table S1).
The evidence is applicable mostly to adults. Pediatric
studies reported no events of QT prolongation after
higher (160 mg/day) or lower (20 mg/d titrated to between
80 mg/day) doses on ziprasidone (37,42).
Olanzapine was examined in four systematic reviews
and meta-analyses and one individual patient data network
meta-analysis. (35,37,38,57,58). We also identified published
and unpublished data from 20 RCTs and 1 non-randomized
trial (30,43,59-79).
Available low-quality evidence suggests that olanzapine
has no effect on QT interval when compared with placebo
in children and adolescents with mental disorders (Table 6).
We also found that that oral olanzapine has no effect on
QT interval while intramuscular olanzapine decreases QT
interval when compared with placebo in adults with mental
disorders (Table 6).
A single small RCT suggests that there are no differences
in QT interval between olanzapine and haloperidol
in children and adolescents with autistic disorder
(Table 7). Moderate quality evidence suggests that there
are no differences in QT interval between olanzapine and
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0
NR

NR

QT prolongation

QT prolongation

QTc prolongation

NR

NR

0

Adjusted RR 1.19
(0.94, 1.51)

Adjusted OR 1.96
(1.02, 2.90)

RR Undetermined

MD 0.38 (−1.50, 2.26);
SMD 0.02 (−0.06, 0.09)

Relative measure of
association
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23

Change in >60 msec; subgroup:
age 30–74 yrs

Table 1 (continued)

1

8

Change in >60 msec; subgroup:
age <30 yrs

Change in > 60 msec and
≥500 msec

23

Change in > 60 msec

42

162

Change in QT 30–60 msec;
subgroup: age >74 yrs

Change in >60 msec; subgroup:
age >74 yrs

143

103

Change in QT 30–60 msec;
subgroup: age <30 yrs

Change in QT 30–60 msec;
subgroup: age 30–74 yrs

137

0

Change in QT 30–60 msec

Risperidone in adults

QTcLD >60 msec

1

50

15

10

22

149

152

50; attributable events
per 1,000 treated 53
[24, 82]

118

0

RR 0.62 (0.09, 4.41)

RR 0.84 (0.47, 1.50)

RR 1.49 (0.72, 3.06)

RR 0.85 (0.26, 2.77)

RR 1.06 (0.70, 1.61)

RR 1.09 (0.81, 1.47)

RR 0.94 (0.75, 1.19)

RR 2.07 (1.33, 3.21);
NNT 19 (12, 42)

RR 1.16 (0.98, 1.37)

RR undetermined

335 (1 RCT) (31,32,36,37)

3,196 (23 studies) (35)

Number of participants
(studies)

4,027 (64 RCTs) (21)

1,005 (64 RCTs) (21)

1,807 (64 RCTs) (21)

1,215 (64 RCTs) (21)

4,027 (64 RCTs) (21)

1,005 (64 RCTs) (21)

1,807 (64 RCTs) (21)

1,215 (64 RCTs) (21)

4,027 (64 RCTs) (21)

257 (1 RCT) (31,32,36,37)

1,006 (1 observational study)
(22)

3,472,494 [1 observational
study of FDA Adverse Event
Reporting System
(FAERS)] (25)

Risperidone higher (1.5–6.0 mg/day) versus lower (0.15–0.6 mg/day) dose in adolescents with schizophrenia

NR

QTc change

NR

Risk with intervention Risk with comparator
per 1,000
per 1,000

Risperidone in children and adolescents

Outcome

Table 1 Risperidone versus placebo on QT interval in people with mental disorders

Low

Low

Low

Low

Low

Low

Low

Low

Moderate

Very low

Very low

Very low

Very low

Low

Quality (GRADE)

No difference

No difference

No difference

No difference

No difference

No difference

No difference

Favors placebo

No difference

No difference

No difference

Favors control (no
risperidone)

No difference

No difference

Comments†
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18

Change in >60 msec and
≥ 500 msec; subgroup:
age >74 yrs

Torsades/QT prolongation
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NR

NR

NR

NR

NR

9; attributable events
per 1,000 treated 8
[4, 13]

5

0

0

Adjusted OR 1.63
(1.50, 1.77)

Adjusted OR 6.96
(5.55, 8.72)

Adjusted MD 0.07
(−0.47, 0.61)

RR 1.90 (1.29, 2.79);
NNT 119 (77, 256)

RR 0.62 (0.09, 4.35)

RR undetermined

RR undetermined

Relative measure of
association

67,992 [1 observational
study of FDA Adverse Event
Reporting System
(FAERS)] (34)

67,992 [1 observational
study of FDA Adverse Event
Reporting System
(FAERS)] (34)

1,017 (1 observational study)
(24)

10,029 (64 RCTs) (21)

1005 (64 RCTs) (21)

1,807 (64 RCTs) (21)

1,215 (64 RCTs) (21)

Number of participants
(studies)

Very low

Very low

Very low

Low

Low

Low

Low

Quality (GRADE)

Favors control
(no risperidone)

Favors control
(no risperidone)

No difference

Favors placebo

No difference

No difference

No difference

Comments†

, we concluded that there is no difference in outcomes between active and control interventions based on P>0.05 and inability to reject null hypotheses but without posthoc analysis of the statistical power to detect true differences. 95% confidence interval in ()/[]; GRADE, Grading of Recommendations Assessment, Development and
Evaluation; OR, odds ratio; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per
1,000 treated as the number of excessive or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated
as absolute rate difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between
intervention and comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and
large (SMD >0.8 standard deviations); QTcLD, interval corrected for heart rate using the population specified linear derived method; NR, not reported.

†

Torsades de Pointes to sudden
cardiac death, >4 cases

Torsades de Pointes and/or QT
interval abnormalities (>4 cases)

NR

0

Change in >60 msec and
≥500 msec; subgroup:
age 30–74 yrs

QTc prolongation

0

Risk with intervention Risk with comparator
per 1,000
per 1,000

Change in >60 msec and
≥500 msec; subgroup:
age <30 yrs

Outcome

Table 1 (continued)
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Table 2 Risperidone versus active comparators on QT interval in people with mental disorders
Outcome

Risk with intervention Risk with comparator Relative measure of
Number of
per 1,000
per 1,000
association
participants (studies)

Quality
(GRADE)

Comments†

Risperidone versus aripiprazole in children and adolescents
QTc, msec, >18 months

NR

NR

MD −1.20 (−8.94,
99 (prospective
6.54); SMD −0.06 analysis registry*) (23)
(−0.46, 0.33)

Very low

No difference

QTc >450 msec, or QTc
prolongation >60 msec,
or QTc dispersion
>100 msec; subgroup:
concomitant stimulant

NR

NR

Adjusted OR 4.23
99 (prospective
(1.10, 17.00)
registry analysis*) (23)

Very low

Favors
aripiprazole

0

0

RR undetermined

Very low

No difference

QTc >500 msec

99 (prospective
analysis registry*) (23)

Risperidone long-acting Injection versus oral atypical antipsychotics (olanzapine, quetiapine, aripiprazole or amisulpride) in adults
QT prolonged

0

11

RR 0.35 (0.01, 8.56)

167 (1 RCT) (39)

Very low

No difference

19

RR 0.94 (0.59, 1.51) 7,573 (64 RCTs) (21)

Very low

No difference

52 (1 RCT) (30,38)

Very low

No difference

58 (1 RCT) (28,29)

Very low

No difference

Very low

No difference

Very low

Favors
risperidone

Risperidone or paliperidone versus active control in adults
Torsades/QT
prolongation

18

Risperidone 16 mg/d versus haloperidol 15 mg/d in adults
QTc >500 msec

0

0

RR Undetermined

Risperidone 4 mg versus risperidone, 2 mg/d + Haloperidol, 2 mg/d in adults
QTc, msec

NR

NR

MD −1.49 (−14.77,
11.79); SMD −0.06
(−0.57, 0.46)

NR

Adjusted HR 1.04
459,614
(0.88, 1.24)
(1 observational study
of medicaid database)
(33)

Risperidone versus olanzapine in adults
Torsades de Pointes,
sudden cardiac death

NR

Risperidone versus ziprasidone in adults
QTc

NR

NR

MD −21.80 (−28.13,
−15.47); SMD −2.76
(−3.90, −1.62)

24 (1 RCT) (26,27)

*, SafEty of NeurolepTics in Infancy and Adolescence (SENTIA) registry (https://sentia.es). †, we concluded that there is no difference
in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without posthoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations
Assessment, Development and Evaluation; OR, odds ratio; NNT, number needed to treat to achieve an outcome in one patient; NNT is
calculated as 1/absolute risk difference; attributable events per 1,000 treated as the number of excessive or avoided events per 1000
treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate difference multiplied by
1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention
and comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard
deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported.
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Risk with intervention
per 1,000
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8
0
0
90
7
3

Peak measured QTc ≥450 msec

Peak measured QTc ≥480 msec

Peak measured QTc ≥500 msec

Maximal QTc change from baseline
≥30 msec

Maximal QTc change from baseline
≥60 msec

Maximal QTc change from baseline
≥75 msec

atm.amegroups.com
0
0
0
0
0

Peak measured QTc ≥480 msec

Peak measured QTc ≥500 msec

Maximal QTc change from baseline
≥30 msec

Maximal QTc change from baseline
≥60 msec

Maximal QTc change from baseline
≥75 msec

27
3
0

Peak measured QTc ≥450 msec

Peak measured QTc ≥480 msec

Peak measured QTc ≥500 msec

Table 3 (continued)

NR

QTc change from baseline

Ziprasidone plus lithium versus placebo plus lithium

24

NR

Peak measured QTc ≥450 msec

QTc change from baseline

Ziprasidone plus lamotrigine versus placebo plus lamotrigine

NR

QT change from baseline

Ziprasidone monotherapy versus placebo

Outcome

0

0

19

NR

0

0

49

0

0

24

NR

1

8

59; attributable events per
1,000 treated 31 [14, 49]

0

0

10

NR

Risk with comparator per
1,000

Table 3 Ziprasidone versus placebo on QT interval in people with mental disorders

RR undetermined

RR 2.38 (0.10, 58.25)

RR 1.43 (0.48, 4.21)

MD 2.10 (−1.32, 5.52);
SMD 0.10 (−0.06, 0.26)

RR undetermined

RR undetermined

RR 0.20 (0.01, 4.04)

RR Undetermined

RR undetermined

RR 1.00 (0.06, 15.45)

MD 2.00 (−4.53, 8.53);
SMD 0.13 (−0.30, 0.57)

RR 2.54 (0.33, 19.50)

RR 0.91 (0.40, 2.06)

RR 1.52 (1.16, 2.01);
NNT 32 [21, 74]

RR 0.64 (0.03, 15.58)

RR 0.64 (0.03, 15.58)

RR 0.78 (0.37, 1.62)

MD 3.90 (2.43, 5.37);
SMD 0.19 (0.12, 0.26)

Relative measure of
association

608 (44)*

608 (44)*

608 (44)*

608 (44)*

82 (44)*

82 (44)*

82 (44)*

82 (44)*

82 (44)*

82 (44)*

82 (44)*

5,217 (44)*

5,217 (44)*

5,217 (44)*

5,217 (44)*

5,217 (44)*

5,217 (44)*

5,217 (44)*

Number of
participants

Very low

Very low

Very low

Low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Low

Very low

Very low

Very low

Low

Quality (grade)

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

Favors placebo

No difference

No difference

No difference

Favors placebo

Comments†
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12
3

Maximal QTc change from baseline
≥60 msec

Maximal QTc change from baseline
≥75 msec
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60

Maximal QTc change from baseline
≥30 msec

0

0

37

0

0

0

NR

7

7

86

Risk with comparator per
1,000

RR undetermined

RR undetermined

RR 1.62 (0.76, 3.45)

RR undetermined

RR undetermined

RR 10.81
(0.63, 186.38)

MD 3.40 (0.71, 6.09);
SMD 0.20 (0.04, 0.36)

RR 0.40 (0.04, 4.35)

RR 1.59 (0.29, 8.60)

RR 1.31 (0.80, 2.15)

Relative measure of
association

631 (44)*

631 (44)*

631 (44)*

631 (44)*

631 (44)*

631 (44)*

631 (44)*

608 (44)*

608 (44)*

608 (44)*

Number of
participants

Very low

Very low

Very low

Very low

Very low

Very low

Low

Very low

Very low

Very low

Quality (grade)

No difference

No difference

No difference

No difference

No difference

No difference

Favors placebo

No difference

No difference

No difference

Comments†

*, individual patient data network meta-analysis of 40 Pfizer-sponsored phase II–IV RCTs in schizophrenia or bipolar disorder patients including 5 pediatric RCTs; †, we
concluded that there is no difference in outcomes between active and control interventions based on P>0.05 and inability to reject null hypotheses but without posthoc analysis of the statistical power to detect true differences. 95% confidence interval in ( )/[ ]; GRADE, Grading of Recommendations Assessment, Development and
Evaluation; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per 1,000 treated as
the number of excessive or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate
difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and
comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8
standard deviations); QTc, corrected QT interval; NR, not reported.

0

0

Peak measured QTc ≥500 msec

Maximal QTc change from baseline
≥75 msec

0

Peak measured QTc ≥480 msec

0

21

Peak measured QTc ≥450 msec

Maximal QTc change from baseline
≥60 msec

NR

QTc change from baseline

Ziprasidone plus valproate versus placebo plus valproate

112

Risk with intervention
per 1,000

Maximal QTc change from baseline
≥30 msec

Outcome

Table 3 (continued)
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Maximal QTc change from baseline
≥60 msec

Maximal QTc change from baseline
≥75 msec
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14
5

Maximal QTc change from baseline
≥60 msec

Maximal QTc change from baseline
≥75 msec

17

23

70

3

7

17

NR

1

3

509 (3 RCTs) (38,47)

569 (4 RCTs) (47)

569 (4 RCTs) (47)

Number of
participants (studies)

RR 0.72 (0.03, 17.67)

RR 0.72 (0.03, 17.67)

RR 2.64 (0.81, 8.59)

MD 4.70 (3.30, 6.10);
SMD 0.23 (0.16, 0.29)

RR 0.28 (0.07, 1.14)

RR 0.59 (0.22, 1.57)

RR 1.16 (0.71, 1.88)

RR 0.15 (0.01, 3.75)

RR 0.23 (0.02, 2.52)

RR 0.46 (0.13, 1.57)

MD 1.10 (−2.59, 4.79);
SMD 0.04 (−0.09, 0.18)

RR 2.88 (0.37, 22.11)

RR 2.40 (0.73, 7.85)

960 (44)*

960 (44)*

960 (44)*

960 (44)*

960 (44)*

960 (44)*

960 (44)*

5,339 (44)*

5,339 (44)*

5,339 (44)*

5,339 (44)*

5,339 (44)*

5,339 (44)*

5,339( 44)*

MD 15.30 (6.22, 24.38); 52 (1 RCT) (38,43)
SMD 0.92 (0.34, 1.49)

RR 0.61 (0.03, 11.80)

RR 4.12 (0.89, 19.09)

RR 1.86 (0.57, 6.04)

60 attributable events per RR 1.51 (1.16, 1.95);
1,000 treated 30 [13, 47] NNT 33 (21, 74)

0

0

3

NR

NR

12

0

11

Relative measure of
association

Very low

Very low

Very low

Very low

Very low

Very low

Low

Very low

Very low

Low

Very low

Very low

Very low

Very low

Very low

Low

Low

Low

Quality
(GRADE)

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

Favors haloperidol

No difference

No difference

No difference

Favors haloperidol

Favors haloperidol

Comments†

*, individual patient data network meta-analysis of 40 Pfizer-sponsored phase II–IV RCTs in schizophrenia or bipolar disorder patients including 5 pediatric RCTs. †, We
concluded that there is no difference in outcomes between active and control interventions based on P value>0.05 and inability to reject null hypotheses but without posthoc analysis of the statistical power to detect true differences. 95% confidence interval in ( )/[ ]; GRADE, Grading of Recommendations Assessment, Development and
Evaluation; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per 1,000 treated as
the number of excessive or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate
difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and
comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8
standard deviations); QTc, corrected QT interval; NR, not reported;

0
81

2

Peak measured QTc ≥480 msec

Maximal QTc change from baseline
≥30 msec

8

Peak measured QTc ≥450 msec

Peak measured QTc ≥500 msec

NR

QTc change from baseline

Ziprasidone, intramuscular

0

0

Peak measured QTc ≥480 msec
90

8

Peak measured QTc ≥450 msec

Maximal QTc change from baseline
≥30 msec

NR

QT change from baseline

Peak measured QTc ≥500 msec

4
NR

QTc prolongation

24

QTc interval ≥480 msec

28

450 msec ≤ QTc interval <480 msec

Risk with intervention Risk with comparator per
per 1,000
1,000

QTc interval ≥450 msec

Ziprasidone oral

Outcome

Table 4 Ziprasidone versus haloperidol on QT interval in people with mental disorders
Annals of Translational Medicine, Vol 6, No 8 April 2018
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8
0
0
90
7
3

Peak measured QTc ≥450 msec

Peak measured QTc ≥480 msec

Peak measured QTc ≥500 msec

Maximal QTc change from baseline ≥30 msec

Maximal QTc change from baseline ≥60 msec

Maximal QTc change from baseline ≥75 msec
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7
3

Maximal QTc change from baseline ≥60 msec

Maximal QTc change from baseline ≥75 msec

7
3

Maximal QTc change from baseline ≥60 msec

Maximal QTc change from baseline ≥75 msec

Table 5 (continued)

90

Maximal QTc change from baseline ≥30 msec

0

Peak measured QTc ≥480 msec
0

8

Peak measured QTc ≥450 msec

Peak measured QTc ≥500 msec

NR

QT change from baseline

Ziprasidone versus olanzapine

90

Maximal QTc change from baseline ≥30 msec

0

Peak measured QTc ≥480 msec
0

8

Peak measured QTc ≥450 msec

Peak measured QTc ≥500 msec

NR

QT change from baseline

Ziprasidone versus chlorpromazine

NR

0

0

66

0

0

0

NR

8

24

226

0

0

16

NR

0

0

51

0

0

9

NR

Risk with intervention Risk with comparator
per 1,000
per 1,000

QT change from baseline

Ziprasidone versus aripiprazole

Outcome

Relative measure of
association

RR 1.94 (0.12, 32.77)

RR 4.74 (0.29, 77.42)

RR 1.37 (0.91, 2.08)

RR 0.23 (0.01, 5.72)

RR 0.23 (0.01, 5.72)

RR 5.21 (0.32, 84.86)

MD 5.30 (3.04, 7.56);
SMD 0.26 (0.14, 0.37)

RR 0.35 (0.05, 2.64)

RR 0.29 (0.09, 0.93)

RR 0.40 (0.28, 0.56)

RR 0.09 (0.00, 2.13)

RR 0.09 (0.00, 2.13)

RR 0.48 (0.12, 1.96)

MD −9.10 (−13.88, −4.32);
SMD −0.43 (−0.61, −0.25)

RR 0.68 (0.04, 11.50)

RR 1.67 (0.10, 27.17)

RR 1.76 (0.80, 3.86)

RR 0.08 (0.00, 2.01)

RR 0.08 (0.00, 2.01)

RR 0.90 (0.12, 6.50)

MD 3.50 (−0.03, 7.03);
SMD 0.17 (−0.02, 0.35)

Table 5 Ziprasidone versus other antipsychotic drugs on QT interval in people with mental disorders

4,640 (44)*

4,640 (44)*

4,640 (44)*

4,640 (44)*

4,640 (44)*

4,640 (44)*

4,640 (44)*

4,430 (44)*

4,430 (44)*

4,430 (44)*

4,430 (44)*

4,430 (44)*

4,430 (44)*

4,430 (44)*

4,423 (44)*

4,423 (44)*

4,423 (44)*

4,423 (44)*

4,423 (44)*

4,423 (44)*

4,423 (44)*

Favors ziprasidone

No difference

No difference

No difference

Favors ziprasidone

No difference

No difference

No difference

No difference

No difference

No difference

No difference

Comments†

Very low

Very low

Low

Very low

Very low

Very low

Low

Very low

No difference

No difference

No difference

No difference

No difference

No difference

Favors olanzapine

No difference

Very low Favors ziprasidone

Low

Very low

Very low

Very low

Low

Very low

Very low

Low

Very low

Very low

Very low

Low

Number of participants Quality
(studies)
(GRADE)
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8
0
0
90
7
3

Peak measured QTc ≥450 msec

Peak measured QTc ≥480 msec

Peak measured QTc ≥500 msec

Maximal QTc change from baseline ≥30 msec

Maximal QTc change from baseline ≥60 msec

Maximal QTc change from baseline ≥75 msec

5

10

108

0

0

3

NR

RR 0.55 (0.12, 2.46)

RR 0.69 (0.24, 1.95)

RR 0.83 (0.62, 1.12)

RR 0.28 (0.01, 6.79)

RR 0.28 (0.01, 6.79)

RR 3.04 (0.42, 22.19)

MD 2.80 (0.35, 5.25);
SMD 0.13 (0.03, 0.24)

Relative measure of
association

4,703 (44)*

4,703 (44)*

4,703 (44)*

4,703 (44)*

4,703 (44)*

4,703 (44)*

4,703 (44)*

Very low

Very low

Low

Very low

Very low

Very low

Low

Number of participants Quality
(studies)
(GRADE)

No difference

No difference

No difference

No difference

No difference

No difference

Favors risperidone

Comments†

*, individual patient data network meta-analysis of 40 Pfizer-sponsored phase II–IV RCTs in schizophrenia or bipolar disorder patients including 5 pediatric RCTs. †, we
concluded that there is no difference in outcomes between active and control interventions based on P value>0.05 and inability to reject null hypotheses but without
post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and
Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the
magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc,
corrected QT interval; NR, not reported.

NR

Risk with intervention Risk with comparator
per 1,000
per 1,000

QT change from baseline

Ziprasidone versus risperidone

Outcome

Table 5 (continued)

Annals of Translational Medicine, Vol 6, No 8 April 2018

© Annals of Translational Medicine. All rights reserved.
Page 11 of 26

atm.amegroups.com

Ann Transl Med 2018;6(8):147

9
NR

QT prolonged

Change in QTc
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0

QTc prolongation >500 msec, 2 hours

atm.amegroups.com
NR

NR

Change in QT, 2 hours after olanzapine 10 mg in
agitated adults with schizophrenia

Change in QT, 2 hours after olanzapine 2.5 mg in
adults with dementia

NR

NR

NR

NR

NR

NR

0

7

21

NR

20

NR

NR

724 (7 RCTs) (58,63-69)

201(1 RCT) (74,75)

869 (6 RCTs) (58,63-69)

1,174 (5 studies) (35,60-62)

MD −0.20 (−5.65, 272 (4 RCTs) (57,63,66,78,79)
5.25); SMD −0.01
(−0.25, 0.23)

MD −7.80 (−12.92, 272 (4 RCTs) (57,63,66,78,79)
−2.68); SMD −0.36
(−0.60, −0.12)

MD −2.70 (−7.92, 270 (4 RCTs) (57,63,66,78,79)
2.52); SMD −0.12
(−0.36, 0.12)

MD −5.30 (−10.54, 270 (4 RCTs) (57,63,66,78,79)
−0.06); SMD −0.24
(−0.48, 0.00)

MD −6.30 (−11.56, 270 (4 RCTs) (57,63,66,78,79)
−1.04); SMD −0.29
(−0.53, −0.05)

MD −5.90 (−10.61, 270 (4 RCTs) (57,63,66,78,79)
−1.19); SMD −0.30
(−0.54, −0.06)

RR Undetermined 556 (4 RCTs) (57,63,66,78,79)

RR 0.73 (0.07, 7.94) 556 (4 RCTs) (57,63,66,78,79)

RR 0.73 (0.18, 2.86) 556 (4 RCTs) (57,63,66,78,79)

SMD −0.14
(−0.29, 0.01)

RR 0.46 (0.04, 4.96)

RR 0.34 (0.16, 0.70)

MD −1.01 (−6.45,
4.43); SMD −0.04
(−0.18, 0.11)

Number of participants
(studies)

No difference

No difference*

No difference

Comments†

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

No difference

Favors
olanzapine

No difference

Favors
olanzapine

Favors
olanzapine

Favors
olanzapine

No difference

No difference

No difference

Moderate No difference

Very low

Low

Very low

Quality
(GRADE)

, we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without
post-hoc analysis of the statistical power to detect true differences. *, no statistically significant differences in absolute risk. 95% confidence interval in ( ); GRADE, Grading
of Recommendations Assessment, Development and Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean
difference between intervention and comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard
deviations), and large (SMD >0.8 standard deviations); QTc, corrected QT interval; NR, not reported.

†

NR

NR

Change in QT, 2 hours after olanzapine 7.5 mg in
agitated adults with schizophrenia

Change in QT, 2 hours after olanzapine 5 mg in
adults with dementia

NR

Change in QT, 2 hours after olanzapine 5 mg in
agitated adults with schizophrenia

NR

5

QTc prolongation >60 msec, 2 hours

Change in QT, 2 hours after olanzapine 2.5 mg in
agitated adults with schizophrenia

15

QTc prolongation >30 msec, 2 hours

Intramuscular olanzapine versus placebo in adults

NR

QT prolonged

Oral olanzapine versus placebo in adults

Change in QTc

NR

Risk with intervention Risk with comparator Relative measure of
per 1,000
per 1,000
association

Olanzapine versus placebo in children and adolescents

Outcome

Table 6 Olanzapine versus placebo on QT interval in people with mental disorders
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Risk with intervention Risk with comparator
per 1,000
per 1,000

0

0

NR
0

Change in QTc

QTc >500 milliseconds

9

0

0

NR

NR
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NR
NR
NR
13
6
0
NR

Change in QT, 2 hours after
olanzapine 5 mg

Change in QT, 2 hours after
olanzapine 7.5 mg

Change in QT, 2 hours after
olanzapine 10 mg

QTc prolongation >30 msec,
2 hours

QTc prolongation >60 msec,
2 hours

QTc prolongation >500 msec,
2 hours

Change in QT, 2 hours

Table 7 (continued)

NR

Change in QT, 2 hours after
olanzapine 2.5 mg

NR

6

0

38

NR

NR

NR

NR

Intramuscular olanzapine versus haloperidol in agitated adults with schizophrenia

QT prolonged

Olanzapine versus haloperidol in adults with bipolar disorder

NR

QT prolonged

Olanzapine versus haloperidol in adults with various mental disorders

QT prolonged

Olanzapine versus haloperidol in children and adolescents with autistic disorder

Outcome

MD −3.70 (−8.25, 0.85);
SMD −0.16 (−0.35, 0.03)

RR 0.18 (0.01, 4.29)

RR 2.64 (0.13, 54.58)

RR 0.35 (0.10, 1.22)

MD −5.80 (−11.53, −0.07);
SMD −0.24 (−0.48, 0.00)

MD −8.40 (−14.14, −2.66);
SMD −0.35 (−0.59, −0.11)

MD −9.40 (−15.16, −3.64);
SMD −0.39 (−0.63, −0.15)

MD −9.00 (−14.26, −3.74);
SMD −0.41 (−0.65, −0.17)

RR 0.57 (0.02, 13.53)

RR Undetermined

SMD −0.13 (−0.34, 0.08)

RR 0.37 (0.13, 1.05)

RR Undetermined

Relative measure of
association

Table 7 Olanzapine versus acive comparators on QT interval in people with mental disorders

476 (4 RCTs)
(57,63,66,78,79)

476 (4 RCTs)
(57,63,66,78,79)

476 (4 RCTs)
(57,63,66,78,79)

476 (4 RCTs)
(57,63,66,78,79)

270 (4 RCTs)
(57,63,66,78,79)

270 (4 RCTs)
(57,63,66,78,79)

270 (4 RCTs)
(57,63,66,78,79)

270 (4 RCTs)
(57,63,66,78,79)

125(1 RCT) (74,75)

51 (1 RCT) (30)

343 (2 RCTs) (58,63-69)

433 (3 RCTs) (58,63-69)

12 (1 RCT) (37,70)

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Moderate

Low

Very low

Number of participants
Quality (GRADE)
(studies)

No difference

No difference

No difference

No difference

Favors olanzapine

Favors olanzapine

Favors olanzapine

Favors olanzapine

No difference

No difference

No difference

No difference

No difference

Comments†
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QTcF prolonged

NR

NR

24

SMD −0.12 (−0.36, 0.12)

RR 0.53 (0.18, 1.53)

RR undetermined; SMD

Relative measure of
association
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0

QTcF ≥500 msec

0

NR

0

0

RR undetermined

RR undetermined

MD −1.57 (−5.84, 2.70);
SMD −0.07 (−0.27, 0.12)

137 (1 RCT) (59)

429 (1 RCT) (73)

329 (1 RCT) (73)

Very low

Very low

Low

Moderate

Very low

Very low

No difference

No difference

No difference

No difference

No difference

No difference

Comments†

, we concluded that there is no difference in outcomes between active and control interventions based on P>0.05 and inability to reject null hypotheses but without posthoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and
Evaluation; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per 1,000 treated as
the number of excessive or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate
difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and
comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8
standard deviations); QTc, corrected QT interval; QTcF, Fridericia’s corrected QT interval; NR, not reported.

†

QTcF ≥450 msec for men or
≥470 msec for women

Olanzapine versus olanzapine combined with lithium, valproate or carbamazepine

NR

Change in QTcF

1,225 (1 RCT) (71)

1,225 (1 RCT) (71)

Number of participants
Quality (GRADE)
(studies)

276 (2 RCTs) (58,63-69)

Olanzapine combined with fluoxetine versus fluoxetine in stabilized adults with treatment-resistant depression

Change in QTc

Olanzapine versus lorazepam in agitated patients

0

QTc ≥500 msec

0

Risk with intervention Risk with comparator
per 1,000
per 1,000

Olanzapine versus asenapine in adults with schizophrenia

Outcome

Table 7 (continued)
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haloperidol, asenapine, or lorazepam in adults with mental
disorders (Table 7). Intramuscular olanzapine decreases QT
interval when compared with haloperidol in agitated adults
(Table 7).
Post-marketing surveillance suggests 84 cases of
prolonged QT intervals and 53 cases of torsades de pointes
tachycardia in people treated with olanzapine among other
medications for various mental disorders (Table S1).
Quetiapine was examined in two systematic reviews and
meta-analyses (38,80). We also identified published and
unpublished data from 7 RCTs and 4 non-randomized
studies (21-40,81-86).
When compared with placebo or no active treatment,
evidence suggests that quetiapine is not associated with
the risk of QT prolongation in children and adolescents
(Table 8). In contrast, quetiapine is associated with higher
odds of torsade’s de pointes or QT interval abnormalities in
adult patients with mental disorders (Table 8).
When compared with other antipsychotics, sparse
evidence suggests that there are no differences in QT
interval between quetiapine and haloperidol or risperidone
(Table 9). Sparse data from a single RCT suggests that
quetiapine decreases QT interval when compared with
ziprasidone in adults with mental disorders (Table 9).
Observational analysis of Medicaid database demonstrates
that quetiapine is associated with the lower risk of torsade’s
de pointes or sudden cardiac death when compared with
olanzapine (Table 9).
Post-marketing surveillance suggests 56 cases of
prolonged QT intervals and 90 cases of torsade’s de pointes
tachycardia in people treated with olanzapine among other
medications for various mental disorders (Table S1).
Aripiprazole was examined in four systematic reviews
and meta-analyses and published and unpublished
data from 12 RCTs and three non-randomized trials
(35-37,60-62,87-97).
Evidence suggests that there are no differences in QT
interval changes or rates of prolonged QT interval between
aripiprazole and placebo, risperidone or haloperidol in
adults with mental disorders (Table 10). Higher dose of
aripiprazole does not increase QT interval when compared
with the lower dose (Table 10). Available studies did not
report the rates of torsade de pointes ventricular tachycardia
in adults treated with aripiprazole. Post-marketing
surveillance identified 15 cases of prolonged QT interval
and 21 cases of torsade de pointes in patients treated with
aripiprazole among other drugs (Table S1).
Sparse evidence suggests that aripiprazole is associated

© Annals of Translational Medicine. All rights reserved.
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with reduction in QT interval in pediatric patients with
mental disorders (Table 11). Sparse evidence suggests that
there are no differences in the rates of prolonged QT
interval between aripiprazole, placebo, risperidone or
pimozide in children and adolescents with mental disorders
(Table 11).
The evidence regarding the role of chronic inflammation
or genetic polymorphism on QT interval in patients taking
aripiprazole is insufficient (98-100).
Aripiprazole may present a safer choice in patients who
need antipsychotic drugs and have no cardiac disorders
associated with higher risk of cardiac death (101).
Brexpiprazole was examined in one systematic review and
unpublished data from four RCTs (102-105).
Evidence suggests that there are no differences in the
rates of the prolonged (>500 msec or increase by >60 msec)
QT interval between brexpiprazole and placebo in adults
with mental disorders (Table 12). Sparse evidence from a
single unpublished RCT suggests that the lower (4 mg)
but not higher (12 mg) dose of brexpiprazole prolongs
QT interval when compared with placebo (Table 12).
The evidence regarding effects of brexpiprazole on QT
interval in children is insufficient. The evidence regarding
comparative safety between brexpiprazole and other
antipsychotics on QT interval or the risk of ventricular
tachycardia is insufficient.
Post-marketing surveillance does not detect cases of
prolonged QT intervals or torsades de pointes tachycardia
in people treated with brexpiprazole among other
medications for various mental disorders (Table S1).
Discussion
Our review of clinical trials, observational studies and postmarketing surveillance found mostly low quality of evidence
concerning higher risk of antipsychotic drugs induced QT
prolongation. In people with mental disorders referred for
treatment with atypical antipsychotic drugs, in order to
avoid QT prolongation and reduce the risk of ventricular
tachycardia clinicians may recommend aripiprazole,
brexpiprazole or olanzapine in licensed doses.
Our findings are in concordance with previously
published observational studies that reported a positive
association between antipsychotic drugs and the increased
risk of cardiac arrest (106-108).
We downgraded the quality of evidence due to the
high risk of bias and small number of events in the RCTs.
The majority of clinical studies did not have statistical

atm.amegroups.com
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NR

QT prolongation
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NR

Torsade’s de Pointes to sudden cardiac
death, >4 cases

NR

NR

NR

NR

45

0

NR

0

NR

NR

Adjusted OR 1.31
(1.23, 1.39)

Adjusted OR 4.78
(3.91, 5.85)

Adjusted MD 0.11
(−0.87, 1.09)

MD 8.10 (1.64, 14.56);
SMD 0.67 (0.14, 1.19)

RR 1.02 (0.10, 10.67)

RR 0.00 (0.00, 0.00)

MD 9.90 (2.10, 17.80)

RR 2.87 (0.12, 70.08)

Adjusted OR 1.39
(0.45, 2.33)

MD 0.62 (−4.15, 5.39);
SMD 0.02 (−0.10, 0.14)

Relative measure of
association

Very low

Quality
(GRADE)

67,992 [1 observational
study of FDA Adverse
Event Reporting System
(FAERS)] (34)

67,992 [1 observational
study of FDA Adverse
Event Reporting System
(FAERS)] (34)

1,017 (1 observational
study) (24)

65 (1 RCT) (81)

65 (1 RCT) (81)

65 (1 RCT) (81)

72 (1 RCT) (80)

546 (3 RCTs) (80,81,86)

No difference

No difference

No difference

Comments†

No difference

No difference

No difference

Very low Favors control, no
quetiapine

Very low Favors control, no
quetiapine

Very low

Very low Favors control, no
quetiapine

Very low

Very low

Very low Favors control, no
quetiapine

Low

3,472,494 [1 observational Very low
study of FDA Adverse
Event Reporting System
(FAERS)] (25)

1,298 (5 studies) (35)

Number of participants
(studies)

, we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without
post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development
and Evaluation; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and
comparator where the magnitude of the effect is defined as small (SMD, 0−0.5 standard deviations), moderate (SMD, 0.5−0.8 standard deviations), and large (SMD >0.8
standard deviations); QTcLD, interval corrected for heart rate using the population specified linear derived method; NR, not reported.

†

NR

NR

Torsade’s de Pointes and/or QT interval
abnormalities (>4 cases)

QTc prolongation

NR

47

QTcLD increase 30–60 msec

QTc changes

0

NR

QTc prolongation

QTcLD >60 msec

3

QT prolongation

Quetiapine in adults

NR

Risk with intervention per Risk with comparator
1,000
per 1,000

Corrected QT (QTc) changes

Quetiapine in children and adolescents

Outcome

Table 8 Quetiapine versus placebo on QT interval in people with mental disorders
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NR

NR

NR

NR

0

0

NR

0

MD −2.10 (−8.43, 4.23);
SMD −0.16 (−0.62, 0.31)

MD −7.00 (−12.25, −1.75);
SMD −0.62 (−1.11, −0.14)

MD −8.20 (−13.38, −3.02);
SMD −0.74 (−1.23, −0.26)

MD −8.30 (−13.48, −3.12);
SMD −0.75 (−1.24, −0.27)

RR undetermined

RR 2.54 (0.10, 62.20)

Adjusted HR 0.73
(0.57, 0.93)

RR undetermined

Relative measure of
association

70 (1 RCT) (82)

70 (1 RCT) (82)

70 (1 RCT) (82)

70 (1 RCT) (82)

70 (1 RCT) (82)

1,082 (1 RCT) (83)

459,614 (1 observational
study of Medicaid programs)
(33)

54 (1 RCT) (30,38)

Number of participants
(studies)

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Quality
(GRADE)

No difference

Favors quetiapine

Favors quetiapine

Favors quetiapine

No difference

No difference

Favors quetiapine

No difference

Comments†

, we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without
post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development
and Evaluation; HR, hazard ratio; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and
comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8
standard deviations); QTc, corrected QT interval; QTcF , Fridericia’s corrected QT interval; NR, not reported.

†

NR

Change in QTc (Bazett)

NR

Change in QTc
NR

NR

Change in QTcF

Change in QTc (FDA)

0

1

NR

0

Risk with intervention Risk with comparator
per 1,000
per 1,000

QTc >60 msec

Quetiapine versus ziprasidone

Electrocardiogram QT
Prolonged

Quetiapine versus risperidone

Torsade’s de Pointes, sudden
cardiac death

Quetiapine versus olanzapine

QTc >500 milliseconds

Quetiapine versus haloperidol

Outcome

Table 9 Quetiapine versus other antipsychotics on QT interval in adults with mental disorders
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47
142
0

QTcF >450 msec

QTcF change from baseline >30 msec

QTcF change from baseline >60 msec

atm.amegroups.com
43

Prolongation of QT interval >30 msec

80

0

30

0

0

133

58

235

58

58

176

58

2

56

0

Risk with comparator
per 1,000

RR 0.54 (0.31, 0.94)

RR undetermined

RR 0.07 (0.00, 1.36)

RR 4.67 (0.24, 88.96)

RR 4.20 (0.19, 92.87)

RR 0.75 (0.08, 7.21)

RR 0.27 (0.01, 6.25)

RR 0.61 (0.16, 2.35)

RR 0.81 (0.05, 12.01)

RR 0.27 (0.01, 6.25)

RR 1.35 (0.37, 4.86)

RR 2.43 (0.28, 21.29)

RR 0.89 (0.08, 9.81)

RR 0.78 (0.47, 1.28)

RR undetermined

Relative measure of
association

1,126 (5 RCTs) (89)

424 (1 RCT) (92)

300 (1 RCT) (91)

29 (1 RCT) (96)

24 (1 RCT) (96)

25 (1 RCT) (96)

39 (1 RCT) (94)

38 (1 RCT) (94)

38 (1 RCT) (94)

39 (1 RCT) (94)

38 (1 RCT) (94)

38 (1 RCT) (94)

1,339 (5 RCTs) (89)

1,339 (5 RCTs) (89)

135 (1 RCT) (90)

Number of participants
(studies)

Low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Low

Low

Very low

Quality
(GRADE)

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

No difference

Comments†

, we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without
post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and
Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the
magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc,
corrected QT interval; QTcF , Fridericia’s corrected QT interval; NR, not reported.

†

0

0

133

100

Prolongation of QT interval

Aripiprazole versus haloperidol

Prolongation of QT interval

Aripiprazole versus risperidone

Electrocardiogram QT corrected
interval prolonged

300 versus 400 mg aripiprazole IM Depot

Electrocardiogram QT corrected
interval prolonged

200 versus 400 mg aripiprazole IM Depot

Electrocardiogram QT corrected
interval prolonged

100

0

QTc Bazett Change from Baseline
>60 msec

200 versus 300 mg aripiprazole IM Depot

238

QTc Bazett Change from Baseline
>30 msec

2

Prolongation of QTc interval
>450 msec
142

43

Prolongation of QT interval >30 msec

QTc Bazett >450 msec

0

Risk with intervention
per 1,000

Prolongation of QT interval during the
study

Aripiprazole versus placebo

Outcome

Table 10 Aripiprazole on QT interval in adults with mental disorders
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NR

62

Corrected QT (QTc) changes

Electrocardiogram QT prolonged at the end
of the study

© Annals of Translational Medicine. All rights reserved.

Prolongation of QT interval

40

NR

0

10

35

NR

0

98 (1 RCT) (37,88)

Number of
participants (studies)

RR 0.33 (0.01, 7.81)

MD 1.60 (−1.66, 4.86);
SMD 0.25 (−0.26, 0.76)

RR undetermined

RR 1.98 (0.18, 21.48)

RR 1.75 (0.17, 18.28)

50 (1CT) (37,87)

60 (1CT) (36,37)

60 (1CT) (36,37)

197 (1 RCT) (37,93)

60 (1 RCT) (95)

MD −2.74 (−4.71, −0.77); 1,776 (4 RCTs and
SMD −0.13 (−0.22, −0.03)
10 non-RCTs)
(35,60-62,88)

RR 7.58 (0.40, 143.03)

Relative measure of
association

Very low

Very low

Very low

Very low

Very low

Low

Very low

Quality
(GRADE)

No difference

No difference

No difference

No difference

No difference

Favors aripiprazole

No difference

Comments†

, we concluded that there is no difference in outcomes between active and control interventions based on P value>0.05 and inability to reject null hypotheses but without
post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and
Evaluation; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and comparator where the
magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8 standard deviations); QTc,
corrected QT interval; NR, not reported.

†

0

NR

QT dispersion (QTd)

Aripiprazole versus pimozide

0

20

Prolongation of QT interval

Aripiprazole versus risperidone

Prolongation of QT interval

Aripiprazole, high dose 30 mg/d versus low dose 10 mg/d

64

Risk with intervention Risk with comparator
per 1,000
per 1,000

Prolongation of QT interval

Aripiprazole versus placebo

Outcome

Table 11 Aripiprazole on QT interval in children and adolescents with mental disorders
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250
81

0
75
19
NR
NR
NR
NR

Increase in QTcF

QTc (>450 msec), brexpiprazole 4 mg

QTc (>480 msec), brexpiprazole 4 mg

QTc (>450 msec), brexpiprazole 12 mg

QTc (>480 msec), brexpiprazole 12 mg

Change in maximum QTc, brexpiprazole
4 mg

Change in summary of maximum minus
mean QTc, brexpiprazole 4 mg

Change in maximum QTc, brexpiprazole
12 mg

Change in summary of maximum minus
mean QTc, brexpiprazole 12 mg

RR 0.63 (0.15, 2.67)

RR 0.83 (0.22, 3.18)

RR 1.04 (0.44, 2.45)

RR 0.43 (0.04, 4.71)

NR

NR

NR

NR

0

0

0

MD 13.50 (9.20, 17.80);
SMD 1.13 (0.74, 1.53)

MD 2.10 (−1.45, 5.65);
SMD 0.22 (−0.15, 0.59)

MD 12.70 (8.95, 16.45);
SMD 1.20 (0.81, 1.58)

MD 1.60 (−1.42, 4.62);
SMD 0.19 (−0.17, 0.54)

RR 3.50 (0.15, 84.16)

RR 10.50 (0.58, 190.65)

RR undetermined

0; attributable events RR 11.00 (0.62, 194.77);
per 1,000 treated 81
NNT 12 [7, 132]
[8, 154]

400

400

7

1

Relative measure of
association

115 (1 RCT) (103)

115 (1 RCT) (103)

124 (1 RCT) (103)

124 (1 RCT) (103)

115 (1 RCT) (103)

115 (1 RCT) (103)

124 (1 RCT) (103)

124 (1 RCT) (103)

17 (1 RCT) (104)

17 (1 RCT) (104)

3,625 (3 RCTS) (103,105)

3,642 (4 RCTS) (103-105)

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Very low

Low

Low

Number of participants
Quality (GRADE)
(studies)

Favors placebo

No difference

Favors placebo

No difference

No difference

No difference

No difference

Favors placebo in
absolute scale

No difference

No difference

No difference

No difference

Comments†

, we concluded that there is no difference in outcomes between active and control interventions based on P value >0.05 and inability to reject null hypotheses but without
post-hoc analysis of the statistical power to detect true differences. 95% confidence interval in ( ); GRADE, Grading of Recommendations Assessment, Development and
Evaluation; NNT, number needed to treat to achieve an outcome in one patient; NNT is calculated as 1/absolute risk difference; attributable events per 1,000 treated as
the number of excessive or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as absolute rate
difference multiplied by 1,000; RCT, randomized controlled trial; RR, relative risk; MD, mean difference; SMD, standardized mean difference between intervention and
comparator where the magnitude of the effect is defined as small (SMD, 0–0.5 standard deviations), moderate (SMD, 0.5–0.8 standard deviations), and large (SMD >0.8
standard deviations); QTc, corrected QT interval; NR, not reported.

†

333

7

QTcB change >60 msec

Increase in QTcB

0

Risk with intervention Risk with comparator
per 1,000
per 1,000

QTc >500 msec

Outcome

Table 12 Brexpiprazole versus placebo on QT interval in adults with mental disorders
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power to detect higher risk of ventricular tachycardia.
We further downgraded the quality of evidence due to
reporting bias because very small proportion of primary
studies that examined benefits of atypical antipsychotics also
examined drug-induced QT prolongation. Retrospective
post-marketing case reports collection is biased because
the reporting depends on clinician opinion regarding
the association between ventricular tachycardia and
administration of antipsychotic drugs (109).
Available industry guidelines recommend intensive
ECG monitoring of QT intervals in clinical trials
of non-antiarrhythmic drugs with suspected proarrhythmic potential but do not require proactive postmarketing monitoring in real-life settings (110). Some
clinical guidelines recommend careful consideration of
individual benefits and harms including drug-induced
QT prolongation in people with mental disorders and
indication for antipsychotic drugs (111-113). Only two
British guidelines and one US guideline meet 2013
Institute of Medicine criteria for trustworthy guidelines
(111-113). Drug labels recommend against administration of
quetiapine or ziprasidone in combination with other drugs
that are known to prolong QT interval and in people with
bradycardia, hypokalemia or hypomagnesemia, congenital
prolongation of the QT interval (114,115). Despite these
recommendations, prevalence of polypharmacy with
multiple pro-arrhythmic drugs is high (2,4,101).
Our review has implications for clinical practice.
Clinicians should evaluate baseline risk for cardiac
arrhythmias before offering atypical antipsychotic
drugs (116). Routine ECG monitoring for the prolongation
of QT interval should be recommended for all patients
under the treatment with atypical antipsychotic drugs (117).
Multidisciplinary coordinated care should be practiced to
avoid polypharmacy with multiple pro-arrhythmic drugs
(116,118). Patients should be proactively examined for clinical
symptoms indicating the occurrence of cardiac arrhythmias,
e.g., dizziness, palpitations, or syncope (119). Our review
has policy implications. Prescribing quality in compliance
with licensed drug use should be routinely evaluated
with electronic decision support systems. (114,115,120).
Proactive technologically advanced pharmacovigilance
applications should be implemented to decrease the risk of
drug-induced QT prolongation and cardiac arrhythmias
(109,121-124).
Our review has research implications. Future proactive
post-marketing surveillance should examine long-term
comparative safety of atypical antipsychotic drugs in

© Annals of Translational Medicine. All rights reserved.
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patients with different age, primary diagnosis and multiple
comorbidities and concomitant drugs. Novel technology
applications and adequate statistical methods should be
used for routine analysis of antipsychotic-induced QT
prolongation and cardiac arrhythmias.
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Supplementary
Table S1 Post-marketing reports of adverse effects associated with antipsychotics (from PharmaPendium.com)
Drug

Adverse effects [case]

Gender [case]

Age [case]

Risperidone

Torsade de pointes [71]

Female [38], Male [26]

20+ [49], <20 [2]

Risperidone

Electrocardiogram QT corrected interval prolonged [43]

Female [23], Male [20]

20+ [26], <20 [4]

Ziprasidone
Hydrochloride

Torsade de pointes [83]

Female [61], Male [19]

20+ [57]

Ziprasidone
Hydrochloride

Electrocardiogram QT corrected interval prolonged [202]

Female [117], Male [63]

20+ [129], <20 [22]

Olanzapine

Torsade de pointes [54]

Female [32], Male [19]

20+ [51]

Olanzapine

Electrocardiogram QT corrected interval prolonged [84]

Female [48], Male [26]

20+ [61], <20 [6]

Quetiapine

Torsade de pointes [90]

Female [68], Male [14]

20+ [79], <20 [1]

Quetiapine

Electrocardiogram QT corrected interval prolonged [56]

Female [28], Male [24]

20+ [39], <20 [9]

Aripiprazole

Torsade de pointes [21 cases]

Female [12], Male [6]

20+ [15], <20 [2]

Aripiprazole

Electrocardiogram QT corrected interval prolonged [15 cases]

Female [6], Male [6]

20+ [6], <20 [4]

Table S2 Mortality and hospitalization in 18,154 adults with schizophrenia treated with ziprasidone or olanzapine [crude results from the
Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)]
Outcome

Risk with intervention Risk with comparator
per 1,000
per 1,000

Relative measure of
association

Quality
(GRADE)

Comments

Non-suicide mortality, 1 year

9

9

RR 1.02 (0.76, 1.39)

Very low

No difference

All-cause mortality, 1 year

11

11

RR 1.01 (0.77, 1.33)

Very low

No difference

Cardiovascular mortality, 1 year

0

1

RR 0.38 (0.10, 1.41)

Very low

No difference

Mortality due to suicide, 1 year

2

2

RR 1.19 (0.61, 2.31)

Very low

No difference

Sudden death, 1 year

0

0

RR 0.67 (0.11, 3.99)

Very low

No difference

151

109

RR 1.39 (1.29, 1.50)

Low

Favors
olanzapine

Hospitalization, arrhythmia, 1 year

1

0

RR 1.75 (0.51, 5.98)

Very low

No difference

Hospitalization, myocardial infarction,
1 year

1

1

RR 1.18 (0.53, 2.64)

Very low

No difference

Hospitalization, diabetic ketoacidosis,
1 year

1

1

RR 1.00 (0.29, 3.45)

Very low

No difference

Hospitalization, all-cause, 1 year

